KLDO

Kaleido Biosciences Inc

KLDO, USA

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

https://kaleido.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KLDO
stock
KLDO

Interesting SQQQ Put And Call Options For May 17th Nasdaq

Read more →
KLDO
stock
KLDO

StockWatch: Kaleido Shares Crater as Company Ceases Operations Genetic Engineering and Biotechnology News

Read more →

Showing 2 of 6

Analyst Ratings & Sentiment

(Last Updated 2023-09-30)

Rating:

BUY

Target Price:

$22

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

1

Strong Sell

1

Finn Analysis

(Last Updated 2023-09-30)

Health Score

Investors

* Institutions hold a combined 1.80% of the total shares of Kaleido Biosciences Inc

1.

Artal Group S A

(1.1743%)

since

2022/06/30

2.

State St US Sm Cap Enhanced SL Cl I

(0.2501%)

since

2022/09/30

3.

Fidelity® Select Biotechnology

(0.1991%)

since

2022/09/30

5.

Northern Small Cap Core K

(0.0334%)

since

2022/09/30

6.

Xtrackers Russell 2000 ETF 1C

(0.0244%)

since

2022/09/30

7.

NT Quality Small Cap Core

(0.0219%)

since

2022/09/30

8.

NT Quality SCC US Fund - L

(0.0219%)

since

2022/09/30

9.

The Vanguard Total Stock Market Index

(0.0106%)

since

2022/02/28

10.

BlackRock Small Cap Index V.I. I

(0.0075%)

since

2022/03/31

11.

MM Russell 2000® Small Cap Index I

(0.0043%)

since

2022/03/31

12.

iShares Russell Small/Mid-Cap Idx K

(0.0034%)

since

2022/03/31

13.

Close Asset Management Limited

(0.0002%)

since

2022/06/30

14.

Rydex Russell 2000 2x Strategy A

(0.0002%)

since

2022/03/31

15.

Rydex Russell 2000 1.5x Strategy H

(0.0001%)

since

2022/03/31

16.

CapTrust Financial Advisors

(0%)

since

2022/06/30

17.

State Street Corporation

(0%)

since

2022/06/30

18.

Palo Alto Investors, LLC

(0%)

since

2022/06/30

19.

Wells Fargo & Co

(0%)

since

2022/06/30

20.

Northern Trust Corp

(0%)

since

2022/06/30

21.

Federated Hermes Inc

(0%)

since

2022/06/30

23.

Barclays PLC

(0%)

since

2022/06/30

24.

Citadel Advisors Llc

(0%)

since

2022/06/30

25.

Millennium Management LLC

(0%)

since

2022/06/30

26.

Harbourvest Partners, LLC

(0%)

since

2022/06/30

27.

BNP Paribas Arbitrage, SA

(0%)

since

2022/06/30

28.

U.S. Bancorp

(0%)

since

2022/06/30

29.

Amalgamated Financial Corp

(0%)

since

2022/06/30

31.

Endurance Wealth Management, Inc.

(0%)

since

2022/06/30

32.

American International Group Inc

(0%)

since

2022/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2022-06-30

EPS Actual

0

EPS Estimate

-0.25

EPS Difference

0.25

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2023-09-30)

Deep Value
Weak Deep Value(0)
Defensive
Cyclical / Risky(3)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0)
Value
Overpriced(0)

Income Statement

(Last Updated 2023-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2023-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.